Table of contents
From the editors
p743 | doi:10.1038/nrc2007
Research Highlights
Tumour suppressors: End of the old guard?
p745 | doi:10.1038/nrc2000
Angiogenesis: Sneaky switch
p746 | doi:10.1038/nrc1993
Genomics: How many genes...?
p746 | doi:10.1038/nrc2001
Vaccines: Everything in moderation
p747 | doi:10.1038/nrc1995
In the news
Armed T cells attack cancer
p747 | doi:10.1038/nrc2006
Viral Tumorigenesis: Viral hijacking
p748 | doi:10.1038/nrc1998
Apoptosis: Activating the executioner
p748 | doi:10.1038/nrc2003
Trial Watch
Chemoprevention with COX2 inhibitors?
p748 | doi:10.1038/nrc2005
In brief
Angiogenesis | Checkpoints | Tumour Suppressors | Angiogenesis
p749 | doi:10.1038/nrc2004
Ageing: Longevity mutations inhibit tumours
p750 | doi:10.1038/nrc1996
Angiogenesis: Moving downstream
p750 | doi:10.1038/nrc2002
Tumorigenesis: Rare and informative
p751 | doi:10.1038/nrc1999
Reviews
How will HPV vaccines affect cervical cancer?
Richard Roden & T.-C. Wu
p753 | doi:10.1038/nrc1973
The FDA recently approved a human papillomavirus preventive vaccine for cervical cancer, the second largest cause of cancer deaths in women. How will the introduction of this vaccine affect cervical cancer incidence and what are the outstanding issues?
Article series: Tumour Microenvironment
Cysteine cathepsins: multifunctional enzymes in cancer
Mona Mostafa Mohamed & Bonnie F. Sloane
p764 | doi:10.1038/nrc1949
Cysteine cathepsins are proteolytic enzymes whose expression is increased in both tumour and tumour-associated cells. What is known about the extracellular and intracellular functions of these enzymes in cancer?
Ubiquitin and ubiquitin-like proteins in cancer pathogenesis
Daniela Hoeller, Christina-Maria Hecker & Ivan Dikic
p776 | doi:10.1038/nrc1994
Ubiquitin and ubiquitin-like proteins (Ubls) participate in many cellular processes, such as apoptosis and DNA repair. How can the deregulation of ubiquitin and Ubls lead to cancer formation, and how might ubiquitin and Ubl pathways be targeted by anticancer therapeutics?
Topoisomerase I inhibitors: camptothecins and beyond
Yves Pommier
p789 | doi:10.1038/nrc1977
Nuclear DNA topoisomerase I (TOP1) is an essential human enzyme, and is the only known target of the camptothecin and its derivatives. The mechanisms and molecular determinants of the tumour response to TOP1 inhibitors are reviewed in the context of developing camptothecin and non-camptothecin derivatives that further increase anti-tumour activity but also reduce side effects.
Mechanisms of cutaneous toxicities to EGFR inhibitors
Mario E. Lacouture
p803 | doi:10.1038/nrc1970
Most cancer patients who are treated with epidermal growth factor receptor inhibitors (EGFRIs) develop dermatological toxicities owing to the important function of the EGFR signalling pathway in the skin. How do EGFRIs affect the skin and what treatments are needed to avoid these undesirable side effects?
Perspective
Timeline
The NCI60 human tumour cell line anticancer drug screen
Robert H. Shoemaker
p813 | doi:10.1038/nrc1951
The US National Cancer Institute (NCI) 60 human tumour cell line anticancer drug screen (NCI60) was developed nearly 20 years ago, and is a valuable source of information about anticancer drug leads and mechanisms of growth inhibition.
Correspondence
Correspondence: Epidemiology of drug interactions in cancer patients
Rachel P. Riechelmann & Monika K. Krzyzanowska
| doi:10.1038/nrc1887-c1
Author Reply: Epidemiology of drug interactions in cancer patients
Charity D. Scripture & William D. Figg
| doi:10.1038/nrc1887-c2
